Acme United Reports Second Quarter 2026 Net Sales Increase of 16% and Net Income Increase of 6%

Solid sales growth, but profit momentum is mixed and segment details are lacking.

What the company is saying

Acme United Corporation is presenting itself as a growth-focused, disciplined operator delivering strong top-line expansion and improved margins. The company highlights a 16% increase in quarterly net sales to $62.7 million and a 15% rise in six-month sales to $115.0 million, emphasizing both organic growth and the contribution from its recent My Medic acquisition. Management frames the My Medic deal as a strategic move, noting its minimal short-term earnings impact due to seasonality but projecting that most of its profitability will materialize in the fourth quarter. The announcement stresses operational execution, citing a 42.6% gross margin (up from 41.0%) and free cash flow generation of $15.5 million over the past year. Acquisitions and investments are positioned as prudent, with $14.5 million spent on My Medic and $1.6 million on a German product line, while a new $65 million syndicated credit facility is described as a sign of financial strength and flexibility. The company’s language is confident but measured, with forward-looking statements clearly identified and caveated. Walter C. Johnsen, Chairman and CEO, is the only notable individual named, signaling continuity and accountability at the top. The overall narrative is designed to reassure investors that Acme United is balancing growth, profitability, and prudent capital management, while acknowledging external risks and the need for ongoing execution.

What the data suggests

The disclosed numbers show robust revenue growth, with quarterly net sales rising from $54.0 million to $62.7 million (16% increase) and six-month sales up from $100.0 million to $115.0 million (15% increase). Excluding the My Medic acquisition, organic sales growth remains healthy at 8% for the quarter and 7% for the half-year. Quarterly net income improved by 6% to $5.1 million, and diluted EPS rose 5% to $1.22, indicating some operational leverage. However, for the six-month period, net income actually declined by 6% to $6.0 million, and diluted EPS fell 7% to $1.46, suggesting that profit growth is not keeping pace with revenue expansion over a longer horizon. Gross margin improved to 42.6% in Q2 2026 from 41.0% a year earlier, and free cash flow generation of $15.5 million over twelve months is a positive sign. The company’s bank debt less cash increased to $27.3 million from $22.8 million, reflecting acquisition activity but remaining manageable relative to cash flow. While headline metrics are well disclosed, the absence of absolute dollar figures for regional and product line sales, as well as a lack of segmental profit data, limits deeper analysis. An independent analyst would conclude that the company is executing well on sales and margin, but the decline in half-year profits and limited segment detail warrant caution.

Analysis

The announcement is largely factual and supported by realised, measurable results: net sales, net income, EPS, gross margin, and free cash flow are all disclosed with period-over-period comparisons. The only forward-looking claim is the expectation that My Medic's profitability will remain weighted to the fourth quarter, which is clearly identified as a projection and not presented as a certainty. The tone is positive but proportionate to the actual results, with no exaggerated language or outsized claims about future performance. While the company did make significant acquisitions and entered a new credit facility, these are reported as completed events, not as aspirational plans. The absence of segmental profit data and the decline in six-month net income temper the overall signal, but the disclosure of both revenue and profit metrics meets the standard for a weak_positive rating. There is minimal narrative inflation and no evidence of hype.

Risk flags

• ●Profit growth is not keeping pace with revenue: While quarterly net income rose 6%, half-year net income declined 6% and EPS fell 7%. This divergence suggests margin pressure or cost increases that could persist, limiting the benefit of top-line growth.
• ●Segmental opacity: The company provides percentage growth rates for regions and product lines but omits absolute dollar values and segmental profit data. This lack of granularity makes it difficult for investors to assess the true drivers of performance or identify underperforming areas.
• ●Acquisition integration and seasonality risk: The My Medic acquisition is highlighted as a growth driver, but its profit contribution is projected to be back-end loaded in Q4. If integration falters or seasonality is more pronounced than expected, the anticipated earnings boost may not materialize.
• ●Rising leverage: Bank debt less cash increased from $22.8 million to $27.3 million, reflecting acquisition spending. While not alarming relative to cash flow, further debt-funded growth or underperformance could strain the balance sheet.
• ●Forward-looking statements and execution risk: The company makes several forward-looking statements about profitability, cost base, and integration. These are subject to risks including inflation, supply chain disruption, and changing consumer habits, as explicitly acknowledged in the announcement.
• ●Geographic and macroeconomic exposure: With operations and acquisitions in the USA, Germany, and Canada, and explicit mention of risks from Ukraine and global trade policies, the company is exposed to currency, regulatory, and geopolitical volatility.
• ●Capital allocation discipline: The company spent $14.5 million on My Medic and $1.6 million on a German product line, but the immediate earnings impact is minimal. If future acquisitions do not deliver timely returns, capital efficiency could come under scrutiny.
• ●Reliance on management projections: The expectation that My Medic will deliver most of its profit in Q4 is a management projection, not a realized fact. Investors should be wary of overweighting this claim until actual results are reported.

Bottom line

For investors, this announcement signals that Acme United is delivering strong sales growth and improving gross margins, but profit momentum is mixed and the full benefit of recent acquisitions remains unproven. The company’s narrative is credible in its reporting of realized results, but the lack of segmental profit detail and the decline in half-year net income temper enthusiasm. The new $65 million credit facility provides financial flexibility, but rising net debt and capital outlays for acquisitions increase the importance of disciplined execution. Walter C. Johnsen’s continued leadership provides stability, but no new institutional investors or strategic partners are disclosed, so there is no external validation of the company’s strategy beyond management’s own statements. To change this assessment, the company would need to provide absolute dollar figures for regional and product line sales, segmental profitability, and clear evidence that acquisitions are accretive to earnings. Key metrics to watch in the next reporting period include Q4 profit contribution from My Medic, consolidated net income and EPS trends, and any signs of margin compression or integration challenges. This announcement is worth monitoring, not acting on immediately, as the investment case hinges on the company’s ability to translate sales growth and acquisitions into sustained profit expansion. The single most important takeaway is that while top-line momentum is real, investors should demand more transparency and proof of bottom-line delivery before increasing exposure.

Announcement summary

(NYSE:ACU) Acme United Corporation announced that net sales for the quarter ended June 30, 2026 were $62.7 million compared to $54.0 million for the quarter ended June 30, 2025, an increase of 16%. Excluding sales resulting from the acquisition of the assets of My Medic on January 15, 2026, comparable three-month sales increased 8%. Net income was $5.1 million, or $1.22 per diluted share, for the quarter ended June 30, 2026, compared to $4.8 million, or $1.16 per diluted share, for the same period last year, an increase of 6% in net income and 5% in diluted earnings per share. Net sales for the six months ended June 30, 2026 were $115.0 million, compared to $100.0 million in the same period in 2025, an increase of 15%. The company paid approximately $14.5 million for the acquisition of the assets of My Medic and purchased the cutting and sharpening line of products in Germany for approximately $1.6 million. On July 15, 2026, the company entered into a new $65 million syndicated credit facility with HSBC Bank USA, N.A and City National Bank, a U.S. subsidiary of Royal Bank of Canada, expiring July 15, 2029. The company projects that My Medic has historically generated the majority of its profitability in the fourth quarter and expects this pattern to continue.

Disagree with this article?